Every material Form 8-K ORAGENICS INC has filed with the SEC since July 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Oragenics said its Chief Medical Officer, James P. Kelly, is scheduled to present on the ONP-002 intranasal concussion candidate at the IPAC-RS 2026 Nasal Innovation Forum on September 17, 2026. The filing is a routine investor-relations update that furnishes the presentation and press release; it reports no new clinical data, financial results, or guidance.
Presentation scheduled for Session 4: Successful Case Studies at 9:40 AM ET on Thursday, September 17, 2026, in Jersey City, New Jersey
Presentation covers ONP-002 development, a Phase IIa feasibility trial enrolling at three sites in Australia, and the proposed U.S. clinical design framework
Company says its IND application submission is anticipated in Q4 2026
Oragenics said NYSE American notified it on August 26, 2026 that it is below the continued listing standards for stockholders' equity. The company reported stockholders' equity of $3.7 million at June 30, 2026, and the exchange requires $6 million because the company had net losses in its five most recent fiscal years. The notice does not immediately affect the listing, but if the company does not meet the requirements, it could face delisting, which the filing says could reduce the stock's liquidity and market price.
Stockholders' equity was $3.7 million at June 30, 2026; the NYSE American standard cited requires $6 million.
A compliance plan is due to NYSE American by September 25, 2026, and the company must regain compliance by February 25, 2028.
Shares continue to trade as OGEN with a ".BC" (below compliance) designation during the plan period.
The company says it will endeavor to undertake a transaction in the future to achieve compliance, but gives no assurance it will succeed.
Oragenics appointed John Spencer, its Senior Controller, as Chief Financial Officer effective July 1, 2026, under an employment agreement with $200,000 base pay and a $25,000 option award. At the June 29, 2026 annual meeting, shareholders re-elected six directors, approved an advisory vote on executive compensation, and authorized the Board to enact a reverse stock split at a ratio between 1-for-2 and 1-for-50 within one year.
John Spencer, age 32, was named CFO effective July 1, 2026, after joining the company in April 2025 as Senior Controller.
Employment agreement provides base compensation of $200,000; Spencer received an option award equal to $25,000.
At the June 29, 2026 annual meeting, the reverse stock split authorization received 1,239,961 votes for and 836,159 against.
Shareholders re-elected six directors and ratified Cherry Bekaert LLP as independent auditors for 2026 (1,887,381 for, 184,883 against).
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every ORAGENICS INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →